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Abstract 42 
Men receiving androgen deprivation therapy (ADT) for prostate cancer (PCa) are likely to develop 43 
metabolic conditions such as diabetes, cardiovascular disease, abdominal obesity and osteoporosis. 44 
Other treatment-related side effects adversely influence quality of life (QoL) including vasomotor 45 
distress, depression, anxiety, mood swings, poor sleep quality and compromised sexual function. The 46 
objective of this study was to systematically review the nature and effects of dietary and exercise 47 
interventions on QoL, androgen deprivation symptoms and metabolic risk factors in men with PCa 48 
undergoing ADT. An electronic search of CINAHL, CENTRAL, Medline, PsychINFO and reference 49 
lists was performed to identify peer-reviewed articles published between January 2004 and 50 
December, 2014 in English. Eligible study designs included randomised controlled trials with pre- and 51 
post-intervention data. Data extraction and assessment of methodological quality with the Cochrane 52 
approach was conducted by two independent reviewers. Seven exercise studies were identified. 53 
Exercise significantly improved QoL, but showed no effect on metabolic risk factors (weight, waist 54 
circumference, lean or fat mass, blood pressure, lipid profile). Two dietary studies were identified, 55 
both of which tested soy supplements. Soy supplementation did not improve any outcomes. No 56 
dietary counselling studies were identified. No studies evaluated androgen-deficiency symptoms 57 
(libido, erectile function, sleep quality, mood swings, depression, anxiety, bone mineral density). 58 
Evidence from RCTs indicates that exercise enhances health- and disease-specific QoL in men with 59 
PCa undergoing ADT. Further studies are required to evaluate the effect of exercise and dietary 60 
interventions on QoL, androgen deprivation symptoms and metabolic risk factors in this cohort. 61 
62 
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Introduction 63 
Prostate cancer (PCa) is the second most commonly diagnosed cancer in men after lung cancers. 64 
According to the International Agency for Research on Cancer, more than 1.1 million cases were 65 
diagnosed in 2012, with highest incidence rates in Australia, New Zealand and Northern America 66 
followed by Western and Northern Europe (Ferlay, et al. 2014). 67 
Managing treatment-related morbidity is increasingly important for men undergoing androgen 68 
deprivation therapy (ADT). In hormone-sensitive PCa, androgens can stimulate the growth of cancer 69 
cells. These effects can be blocked or reduced through the use of surgical or medical ADT, shrinking 70 
the tumour or slowing tumour growth. This therapy is common for the management of metastatic PCa 71 
and as an adjuvant therapy in localised PCa. With the exception of primary ADT in men with localized 72 
PCa (Sammon, et al. 2015), the use rates of ADT in Australia and the United States of America are 73 
rising, with this therapy being offered earlier in the cancer trajectory (Grossmann, et al. 2011). 74 
Compared with no treatment, ADT is associated with an increased risk in non-cancer mortality in men 75 
over 66 years with localised disease (Abdollah, et al. 2015). These men are more likely to develop 76 
metabolic conditions such as diabetes, cardiovascular disease and abdominal obesity; or experience 77 
further life-limiting morbidities such as osteoporosis. Treatment-related side effects include vasomotor 78 
distress, depression and anxiety, mood swings, poor sleep quality and compromised libido and 79 
erectile function leading to diminished function and quality of life (QoL) (Grossmann et al. 2011). 80 
Evidence indicates that the effects of ADT can be attenuated through specific health behaviours. The 81 
current Nutrition and physical activity guidelines for cancer survivors (Rock, et al. 2012) recommend 82 
that for all cancers, nutrition, physical activity, stress and sleep assessment should commence as 83 
soon as possible after diagnosis, and account for current and anticipated preferences, symptoms and 84 
lifestyle needs. In cancer survivors, exercise has been shown to improve cardiovascular fitness, 85 
muscle strength, body composition, fatigue, anxiety, depression and some aspects of QoL (Rock et 86 
al. 2012). Similarly, an individualised multidisciplinary approach including dietetics and exercise 87 
physiotherapy was recommended in the joint consensus statement from the Endocrine Society of 88 
Australia, the Australian and New Zealand Bone and Mineral Society, and the Urological Society of 89 
Australia and New Zealand (Grossmann et al. 2011). 90 
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In a previous meta-analysis, Chipperfield et al. (Chipperfield, et al. 2014) evaluated the effect of 91 
physical activity on outcomes such as depression, anxiety, cognitive function and QoL while excluding 92 
studies of other outcomes or those including dietary interventions. There are no meta-analyses of 93 
high level evidence that evaluate the effect of dietary and/or exercise interventions in preventing or 94 
ameliorating ADT-related metabolic and other side effects beyond those relating to QoL. 95 
The aim of this review is to examine the effectiveness of dietary and/or exercise in preventing, 96 
modifying or managing the effects of ADT in men with PCa. Specifically, the primary objective is to 97 
investigate the effect of these interventions on QoL, and the secondary objectives are to evaluate the 98 
effects on androgen deprivation symptoms and metabolic risk factors. 99 
  100 
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Materials and methods 101 
Eligibility criteria 102 
To address the review objectives, we included randomised controlled trials (RCTs) of participants who 103 
were adult (>18 years of age) human males with PCa undergoing ADT. Studies with participants not 104 
undergoing ADT, and whose data were reported separately, were included. Interventions of interest 105 
compared aerobic exercise, resistance exercise and/or dietary counselling with standard care or no 106 
treatment; and dietary supplements were compared with matched placebo. Primary outcome 107 
measures were health-related QoL (overall physical or mental health) and disease-specific QoL (QoL 108 
in the context of PCa) as measured by validated questionnaires. Secondary outcome measures of 109 
androgen deprivation symptoms were dual X-ray absorptiometry (DXA) scans of bone mineral 110 
density, vasomotor symptoms, insomnia and mood swings, weight gain, depression and anxiety. 111 
Secondary outcome measures of metabolic risk factors were fasting glucose, fasting lipid profile 112 
and/or fat mass measured by DXA. 113 
Search methods 114 
A search of Medline was undertaken (Table 1) to identify relevant text words and index terms used to 115 
describe the articles. A second search of CINAHL, Cochrane CENTRAL, Medline and PsychINFO 116 
was conducted using identified text words and index terms. Reference lists of relevant articles were 117 
hand searched for additional studies that met the inclusion criteria. Only articles published in the 118 
English language between 2004 and 2014 were included. 119 
Data collection and extraction 120 
One author (LT) analysed the titles and abstracts from the searches. Full text was sought for studies 121 
that both potentially met the eligibility criteria and, where eligibility could not be determined due to 122 
insufficient information. Two authors (AM and LT) independently assessed eligibility from the full text, 123 
any disagreements were resolved by discussion and consensus.  124 
Two review authors (AM and LT) independently extracted data from each study using a template 125 
developed by the authors for the purpose of the review. Data extracted included descriptions of 126 
general study information, methods, participants, intervention and comparator, outcomes and length 127 
of follow-up, study results for each outcome, and time of assessment. Any discrepancies between 128 
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review authors were discussed and corrected by consulting the original article. For studies published 129 
more than once, data was collated. Where data for an outcome was reported more than once, the 130 
data from the publication with the largest study population was used. 131 
Assessment of risk or bias 132 
Two review authors (AM and LT) independently assessed the risk of bias of the included studies 133 
using the Cochrane Collaboration’s tool for assessing risk of bias (Higgins and Green 2011). This tool 134 
assesses random sequence generation, allocation concealment, blinding of participants and 135 
personnel, blinding of outcome assessment, incomplete outcome data and selective reporting. Each 136 
study was graded according to low, high or unclear risk of bias. 137 
Data synthesis 138 
Where possible, data were used to calculate the mean difference (MD) using the mean for continuous 139 
outcomes with number of participants as the denominator for each outcome. Where different scales 140 
were used, the standardised mean difference (SMD) was calculated. Where the standard deviation of 141 
the change scores was not given, they were imputed using the standard deviation from similar studies 142 
(Higgins and Green 2011). 143 
Obvious clinical heterogeneity was assessed by comparing populations, settings, interventions and 144 
outcomes before deciding whether it was appropriate to pool studies. Where pooling was undertaken, 145 
statistical heterogeneity was assessed with the I
2
 statistic. Where it was reasonable to assume a 146 
single pooled effect (I
2
 < 50%), a fixed-effect model was used. Where variation in populations and 147 
interventions, or substantial heterogeneity (I
2
  ≥ 50%) was evident, a random-effects model was used 148 
(DerSimonian and Laird 1986). Review Manager 5.3® was used for statistical analysis. Where 149 
statistical pooling was not possible, findings are presented in narrative form. 150 
 151 
Results 152 
Of the 246 potential articles, 13 met the inclusion criteria (Figure 1), providing data for 9 intervention 153 
studies. Intervention characteristics and key findings are summarised in Table 2. The median sample 154 
size was 100 (33-121) participants with median intervention duration of 12 (12-24) weeks. Although 155 
participant eligibility criteria were similar, cancer stage and treatment varied between studies, as did 156 
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the depth of information provided about these variables. Only three of the nine studies provided 157 
details on the duration of ADT. Risk of bias (Figure 2) was low, with the exception of Uth et al. (Uth, et 158 
al. 2014) who reported significant differences between groups at baseline and lacked both allocation 159 
concealment and outcome assessment blinding. As expected for lifestyle-based interventions, the 160 
largest risk of bias was lack of blinding of participants. 161 
There were also studies that lacked adequate information for domains of risk of bias assessment. 162 
Lack of details pertaining to both random sequence generation and allocation of concealment, 163 
potentially introduced selection bias. Where studies failed to report blinding of outcome assessors, 164 
they introduced potential detection bias. In addition, incomplete outcome data and selective reporting 165 
may have increased the risk of attrition and reporting bias. 166 
Interventions 167 
Seven RCTs investigated the effects of exercise on QoL, androgen deprivation symptoms and/or 168 
metabolic risk factors in men with PCa (Alberga, et al. 2012; Bourke, et al. 2011; Bourke, et al. 2014; 169 
Cormie, et al. 2013; Culos-Reed, et al. 2010; Galvao, et al. 2014; Galvao, et al. 2010; Segal, et al. 170 
2009; Uth et al. 2014). Four studies included intervention groups that combined resistance exercise 171 
training (RET) and aerobic exercise training (AET) (Bourke et al. 2011; Bourke et al. 2014; Galvao et 172 
al. 2014; Galvao et al. 2010), two studies used only RET (Alberga et al. 2012; Culos-Reed et al. 2010; 173 
Segal et al. 2009), one study used AET (Alberga et al. 2012; Segal et al. 2009) and one used football 174 
training sessions (Uth et al. 2014). Participants in the interventions involving AET, trained at an 175 
intensity ranging from 55% to 85% of maximal heart rate or 11-15 points on the Borg Rating of 176 
Perceived Exertion Scale. Most studies of RET did not report exercise intensity. Of those that did, 177 
participants trained at 60-70% of one repetition maximum. 178 
Two dietary RCTs of 99 participants investigated the efficacy of 12 weeks of soy supplementation on 179 
QoL, androgen deprivation symptoms or metabolic risk factors in men with PCa (Napora, et al. 2011; 180 
Sharma, et al. 2009; Vitolins, et al. 2013). One study had four treatment groups randomising 181 
venlafaxine and venlafaxine placebo as well as soy and soy placebo (Vitolins et al. 2013). For this 182 
review, we only included the treatment groups where venlafaxine placebos were used so as to 183 
compare the effects of soy supplementation. 184 
Quality of life 185 
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Health- related QoL was reported in five exercise studies of 427 participants (Alberga et al. 2012; 186 
Bourke et al. 2011; Culos-Reed et al. 2010; Galvao et al. 2014; Galvao et al. 2010). Disease-specific 187 
QoL was reported in three exercise studies of 271 participants (Alberga et al. 2012; Bourke et al. 188 
2011; Bourke et al. 2014). There was no significant clinical or statistical heterogeneity (I
2
=0%) and the 189 
overall risk of bias was low. Quantitative analysis showed that exercise improved health- related QoL 190 
(SMD=0.29; 95%CI = 0.10, 0.49) and disease-specific QoL (SMD=0.36; 95%CI = 0.11, 0.61) in men 191 
with PCa undergoing ADT (Figure 3 and Figure 4, respectively). 192 
Health-related QoL was reported in both dietary intervention studies. There was no significant clinical 193 
or statistical heterogeneity (I
2
=0%) and the risk of bias was low. Soy supplementation did not 194 
significantly improve health-related QoL (SMD = 0.01; 95% CI = -0.38, 0.41). Only Vitolins et al. 195 
(Vitolins et al. 2013) evaluated disease-specific QoL, reporting that soy supplementation significantly 196 
improved FACT-P global score versus placebo (112.5 ± 6.0 versus 103.8±6.2, p=0.048). 197 
Androgen deprivation symptoms 198 
No exercise intervention evaluated libido, erectile function, sleep quality and insomnia, mood swings, 199 
depression or anxiety or bone mineral density. Both dietary intervention studies evaluated the effect of 200 
soy supplementation on vasomotor distress. Sharma et al. (Sharma et al. 2009) reported a significant 201 
difference in hot flash scores between groups, but within-group analysis showed no significant 202 
improvement in vasomotor distress score in either the placebo or the soy arms due to the imbalance 203 
in scores at baseline. Similarly, Vitolins et al. found soy supplementation did not significantly improve 204 
hot flash number, severity or hot flash score versus placebo (Vitolins et al. 2013). One dietary 205 
intervention study evaluated libido, erectile function and sleep quality but found no significant 206 
improvements with soy supplementation (Napora et al. 2011; Sharma et al. 2009). No dietary studies 207 
evaluated insomnia, mood swings, depression, anxiety or bone mineral density. 208 
 209 
Metabolic risk factors 210 
Four exercise intervention studies totalling 310 participants evaluated the effect of exercise on body 211 
weight. There was no significant clinical or statistical heterogeneity (I
2
=0%) and the overall risk of bias 212 
was low. Quantitative analysis showed that exercise did not significantly improve total body weight 213 
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(MD = 0.26; 95% CI = -2.40, 2.93) (Bourke et al. 2011; Bourke et al. 2014; Galvao et al. 2014; Galvao 214 
et al. 2010). One exercise intervention study evaluated waist-hip ratio, but showed no differences 215 
between the intervention and control groups (Bourke et al. 2011). Similarly, exercise did not 216 
significantly improve waist circumference measures, which were reported in two studies with a 217 
combined total of 200 participants (MD = -0.38; 95% CI = 2.97, 2.22) (Culos-Reed et al. 2010; Galvao 218 
et al. 2014). Body composition, as measured by DXA, was reported in seven exercise intervention 219 
studies. There was no significant clinical or statistical heterogeneity (I
2
=0%) and the overall risk of 220 
bias was low. Exercise did not significantly improve any body composition measure including lean 221 
body mass (MD = -0.20; 95% CI = -1.72, 1.32) (Alberga et al. 2012; Galvao et al. 2014; Galvao et al. 222 
2010; Uth et al. 2014), total fat mass (MD = -0.61; 95% CI = -2.48, 1.26) (Galvao et al. 2014; Galvao 223 
et al. 2010; Uth et al. 2014) or percentage fat mass (MD = -0.71; 95% CI = -1.96, 0.55) (Alberga et al. 224 
2012; Galvao et al. 2014; Galvao et al. 2010; Uth et al. 2014).  225 
One dietary intervention study evaluated body weight and body mass index but found no significant 226 
improvements with soy supplementation (Napora et al. 2011; Sharma et al. 2009). Neither dietary 227 
intervention evaluated the effect of soy supplementation on body composition. 228 
Three intervention studies with a combined total of 300 participants reported that exercise did not 229 
significantly improve systolic blood pressure (MD = 1.72; 95% CI = -2.47, 5.90) (Bourke et al. 2014; 230 
Culos-Reed et al. 2010; Galvao et al. 2010). Similarly, exercise did not significantly improve blood 231 
glucose levels (MD = 0.13; 95% CI =  -0.16, 0.43), total cholesterol (MD = 0.13; 95% CI = -0.18, 0.44), 232 
triglycerides (MD = -0.06; 95% CI = -0.27, 0.15), low-density lipoprotein (LDL) cholesterol (MD = 0.06; 233 
95% CI = -0.20, 0.32) or high-density lipoprotein (HDL) cholesterol (MD = 0.06; 95% CI = -0.05, 0.16). 234 
Only one dietary intervention study evaluated the effect of soy supplementation on lipid profile. Soy 235 
supplementation did not significantly improve total cholesterol, triglycerides, LDL cholesterol or HDL 236 
cholesterol. Neither dietary supplement studies evaluated the effect of soy on glucose levels. 237 
 238 
Discussion 239 
Exercise 240 
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Exercise interventions conducted over 12 to 24 weeks and which consisted of two to three days per 241 
week of combined aerobic and resistance exercise, were associated with significant improvements in 242 
health- and disease-specific QoL in men with PCa receiving ADT. Despite these improvements, the 243 
magnitude of effect of exercise on these outcomes was small to moderate. The majority of included 244 
studies implemented resistance and aerobic exercise as a combined intervention, so it was not 245 
possible to determine whether this improvement was attributable to the one type of exercise or the 246 
synergy of both. These results are consistent with the meta-analysis by Chipperfield et al. 247 
(Chipperfield et al. 2014) who reported preliminary data indicating that physical activity significantly 248 
improved QoL. However, in the present analysis there were no corresponding improvements in any 249 
secondary outcomes. A possible explanation lies in the studies’ designs. Exercise intervention studies 250 
are often at much greater risk of performance bias compared with other randomised trial designs due 251 
to the use of usual care or waitlist control groups, as well as the logistical inability to blind participants 252 
and interventionists. Moreover, those in the exercise groups had longer and more intense contact with 253 
interventionists, a degree of health professional contact that could have improved perceptions of QoL 254 
independent of the effect of exercise. Therefore, improvements in these outcomes may have been 255 
masked by a variability in the types of exercise, intensity of the intervention and the duration of the 256 
interventions. 257 
Bone fracture is a major risk factor for increased mortality. Depleted testosterone and oestrogen 258 
levels in men with prostate cancer undergoing ADT can lead to bone loss (Higano 2004). These 259 
changes increase bone resorption and suppress bone formation, increasing the risk of fracture 260 
(Higano 2008; Michaud 2010). Despite the well-established effect of ADT on bone mineral density, 261 
there were a notable lack of studies evaluating the effect of exercise on this outcome. Similarly, other 262 
androgen deficiency symptoms including hot flashes, sexual function, sleep quality, depression and 263 
anxiety were often not reported as outcomes. These findings are consistent with Chipperfield et al, 264 
(Chipperfield et al. 2014) who also identified no studies evaluating the effect of physical activity on 265 
anxiety and depression.  266 
Although ADT is associated with reduced PCa-specific mortality, its association with increased risk of 267 
non-cancer mortality, metabolic parameters and body composition could lead to the development of 268 
metabolic syndrome. Metabolic syndrome is a cluster of cardiovascular risk factors including insulin 269 
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resistance, increased triglycerides and fasting glucose, low HDL, increased waist circumference and 270 
hypertension. It is implicated in the development of diabetes and cardiovascular disease. In addition 271 
to metabolic syndrome, large cohort analyses have demonstrated that serum cholesterol is 272 
independently associated with cardiovascular mortality (Lewington, et al. 2007; Stamler, et al. 1986). 273 
Interestingly, although associated with the development of diabetes (Saylor and Smith 2009), the 274 
effect of ADT on the risk of developing cardiovascular disease is unclear. ADT increases a number of 275 
cardiovascular risk factors, including elevated fasting insulin; decreased insulin sensitivity; worsened 276 
lipid profile (Isidori, et al. 2005; Laughlin, et al. 2008; Traish, et al. 2009; Whitsel, et al. 2001); 277 
hypertension (Svartberg, et al. 2004); and abdominal obesity (Marin, et al. 1993). In a large meta-278 
analysis of observational studies, Zhao et al. (Zhao, et al. 2014) reported a non-significant 10% 279 
increase in cardiovascular disease risk (HR = 1.10; 95% CI = 1.00, 1.21; p = 0.06) but a significant 280 
association with cardiovascular mortality (HR = 1.17; 95% CI = 1.04, 1.32; p = 0.01). Conversely, in a 281 
meta-analysis of randomised controlled trials (Nguyen, et al. 2011), the relative risk of cardiovascular 282 
death for men undergoing ADT for PCa versus control was not significant (RR = 0.93; 95% CI = 0.79, 283 
1.10; p = 0.41). The discrepancy between these two analyses could be explained by differences in 284 
risk. Compared with patients with more advanced disease, low risk patients have a higher life 285 
expectancy and are less likely to die of their cancer and therefore live long enough for cardiovascular 286 
disease to become a problem.  287 
We found that exercise did not significantly improve lipid profiles, blood glucose levels, blood 288 
pressure, body weight or body composition. It is possible that too few studies were included in the 289 
current meta-analysis, thereby providing insufficient data or sample size to identify any ameliorative 290 
effect of exercise on these outcomes. 291 
Weight gain in men undergoing ADT for PCa over 12 to 24 weeks would likely be minimal. Seible et al 292 
(Seible, et al. 2014) reported that even one year after ADT initiation, weight gain was clinically 293 
insignificant (1.32±4 kg, p = 0.0005). Contrary to traditional beliefs about risk groups, Seible et al. 294 
(Seible et al. 2014) has previously reported that the independent predictors of weight gain in this 295 
population include a non-obese BMI and a relatively young age (i.e., <30kg/m
2
 and <65 years old, 296 
respectively). The mean sample ages of the studies analysed in this review were over 65 years, with 297 
most centring around 70 years. The inclusion of studies of older populations could have 298 
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unintentionally obfuscated any larger weight alterations in the younger participants, resulting in 299 
smaller mean weight changes. 300 
It is also possible that any losses in fat mass may have been obscured by gains in lean tissue. In men 301 
undergoing ADT, significant weight and body composition changes tend to occur within the first few 302 
months of treatment initiation and continue for 1-2 years. In an observational study, Smith et al. 303 
(Smith, et al. 2002) reported that men undergoing 48 weeks of ADT experienced significant increases 304 
in percentage body fat (9.4±1.7%, p<0.001) and significant decreases in percentage lean body mass 305 
(2.7±0.5%, p<0.001). In the current study, despite most studies’ eligibility criteria including men who 306 
had been undergoing ADT for at least 2-6 months, exercise did not significantly improve fat mass or 307 
lean body mass. However, similar to weight changes, it is possible that too few studies were included 308 
in the current analysis to capture such small changes or that intervention periods were too short to 309 
capture the effect of exercise on body composition. 310 
Diet 311 
The precise contribution of sex steroid deprivation to the adverse effects of ADT is unclear. Low 312 
testosterone has been implicated in diminished QoL, androgen-deficiency symptoms and metabolic 313 
risk factors in men with PCa on ADT; however, these men also have low oestradiol levels (Sharma et 314 
al. 2009). It is hypothesised that due to the structural similarity of isoflavones (soy protein) to 315 
oestrogen, soy could induce a weak oestrogenic effect, minimising these adverse effects. In this 316 
review, soy supplementation did not significantly improve health-related QoL and there were 317 
insufficient data to quantitatively address disease-specific QoL. There were also insufficient data to 318 
evaluate the effect of soy on androgen deficiency symptoms, with the exception of vasomotor 319 
distress. Consistent with previous trials, soy supplementation did not significantly improve vasomotor 320 
distress. In breast cancer, soy has been shown to have no effect on the menopausal symptoms of 321 
postmenopausal women (MacGregor, et al. 2005; Quella, et al. 2000; Van Patten, et al. 2002). There 322 
were insufficient data to evaluate the effect of soy on metabolic risk factors. 323 
Strengths and limitations 324 
This systematic review includes a quantitative analysis of randomised controlled trials, the highest 325 
level of evidence for interventions. Where studies were combined, there was minimal clinical and 326 
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statistical heterogeneity. Data extraction and risk of bias assessment was conducted independently 327 
by two reviewers and almost all studies were found to have a low risk of bias. 328 
The findings of this review were limited, however, by the lack of dietary intervention studies, 329 
particularly those using dietary counselling. Exercise interventions could not be evaluated by exercise 330 
type (i.e., resistance versus aerobic) so any significant results should be considered preliminary and 331 
attributed to combined modality. 332 
Conclusion 333 
There are significant gaps in the literature with regards to dietary and exercise interventions for the 334 
management of QoL, androgen deficiency symptoms and metabolic risk factors in men receiving ADT 335 
for prostate cancer. Although the effects of exercise interventions on QoL are apparent, it is unclear 336 
whether these improvements are attributable to increased interventionist contact, aerobic exercise, 337 
resistance exercise, or the combination of all three. More studies are required that control for 338 
interventionist contact as well as exercise type (i.e., aerobic or resistance), intensity and duration. 339 
There is also a clear gap in the literature as to the effect of dietary counselling on QoL, androgen 340 
deficiency symptoms and metabolic risk factors in men undergoing ADT. No dietary studies 341 
addressing the effects of dietary counselling on ADT symptom management were identified for this 342 
review. It is possible that either the dietary counselling studies are addressing outcomes which have 343 
little relevance to ADT symptom management or they do not exist. 344 
Despite the findings of this review, interventions that are effective in this population are still needed to 345 
ameliorate or manage the adverse effects of ADT. This is particularly important for decreasing this risk 346 
of cardiovascular disease and diabetes through managing metabolic risk factors and addressing bone 347 
mineral density. 348 
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Figure Legends 
Figure 1. PRISMA flowchart. 
Figure 2. Risk of bias summary. Red (-), high risk of bias; Yellow (?), unclear risk of bias; Green (+) 
low risk of bias. 
Figure 3. Forest plot of comparison: exercise versus usual care on health-related quality of life. 
Figure 4. Forest plot of comparison: exercise versus usual care on disease-specific quality of life. 
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Table 1 Mesh and keywords used to search for publications in Ovid MEDLINE® 1946 to Present. 1 
Subject MeSH and keywords 
Prostate Cancer “Prostatic Neoplasms” [MeSH] or prostate cancer  
Dietary interventions “Diet” [MeSH] or “Diet Therapy” [MeSH]  
Dietary supplements “Isoflavones” [MeSH] or isoflavones or “Flax” [MeSH] or flaxseed or “Soy Milk” [MeSH] or “Soy Foods” [MeSH]/ or 
soy or “Soybean Proteins” [MeSH] or “Carotenoids” [MeSH] or “Vitamin E” [MeSH] or lycopene or “Folic Acid” 
[MeSH] or folate or “Dietary Supplements” [MeSH] or “Complementary Therapies” [MeSH] or “Naturopathy” 
[MeSH] 
Fruit, vegetables and fibre “Fruit” [MeSH] or fruit or “Vegetables” [MeSH] or vegetables or “Dietary Fiber” [MeSH] or dietary fibre  
Dairy, meat and fat “Dairy Products” [MeSH] or dairy or “Calcium, Dietary” [MeSH] or “Meat” [MeSH] or “Dietary Fats” [MeSH] 
Exercise interventions “exercise” [MeSH] or “physical endurance” [MeSH ] or “Exercise Therapy” [MeSH] 
Search limits English language, 2004-current, all adult (19 plus years) 
 2 
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Table 2:  Study characteristics and key findings 1 
First Author, 
year 
Design Sample Duration of 
ADT 
Intervention duration and  
frequency 
Intervention form and dose Control Key findings 
intervention 
versus control 
Bourke, 2011 
(Bourke et al. 
2011) 
2-arm 50 ≥6 months 12 weeks; supervised 2 
days/week (weeks 1-6) to 1 
day/week (weeks 7-12), 
unsupervised 1 day/week 
(weeks 1-6) to 2 days/week 
(weeks 7-12); optional 
dietary counselling 
1day/fortnight 
30 minutes supervised AET at 
55-85% predicted MHR or 11 to 
15 Borg Rating of Perceived 
Exertion Scale + 2-4 sets 
supervised RET + 30 minutes 
unsupervised exercise + optional 
15-20 minutes small group 
dietary counselling. 
Usual care ↔ HRQoL
(a)
 
↔ DQoL
(b)
 
↓ fatigue
(c) 
↔ BW, BMI or 
WHR 
↔ systolic or 
diastolic BP 
Bourke, 2014 
(Bourke et al. 
2014) 
2-arm 100 33±33 months 
(intervention), 
30±30 months 
(control) 
12 weeks; supervised 2 
days/week (weeks 1-6) to 1 
day/week (weeks 7-12), 
unsupervised 1 day/week 
(weeks 1-6) to 2 days/week 
(weeks 7-12); dietary 
counselling 1day/fortnight 
30 minutes supervised AET at 
55-75% predicted MHR or 11-13 
Borg Rating of Perceived 
Exertion Scale + 2-4 sets of 8-12 
repetitions of supervised RET 
(60% 1 RM)+ 30 minutes 
unsupervised exercise + 20 
Usual care ↑DQoL
(b) 
↑ fatigue
(c) 
↔ BW or BMI 
↔ systolic or 
diastolic BP 
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First Author, 
year 
Design Sample Duration of 
ADT 
Intervention duration and  
frequency 
Intervention form and dose Control Key findings 
intervention 
versus control 
minutes small group dietary 
counselling 
Culos-Reed, 
2010 (Culos-
Reed et al. 
2010) 
2-arm 100 ≥6 months 16 weeks; supervised 
booster session 1 day/week 
unsupervised 3 to 5 
days/week. 
Supervised and unsupervised 
exercise sessions of walking, 
stretching, “light” RET. 
Supervised group sessions of 60 
minute exercise + 30 minute 
education. Unsupervised 
“moderate” exercise 
Usual care ↔ QoL
(e) 
↔ Fatigue
(k) 
↔ 
Depression
(g)
 
↔ hormone 
symptoms
(j) 
↔ BMI 
↓ WC 
↔ systolic or 
diastolic BP 
Galvao, 2010 
(Galvao et al. 
2010); 
Cormie, 2013 
2-arm 57 ≥2 months 12 weeks; supervised 2 
days/week + unsupervised 
150 minutes/wk.. 
2-4 sets of supervised RET (12 
RM to 6 RM) in small groups + 
15-20 minutes supervised AET at 
65-80% MHR and 11-13 Borg 
Usual care ↑ QoL
(d) 
↔ libido, 
urinary or 
bowel 
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First Author, 
year 
Design Sample Duration of 
ADT 
Intervention duration and  
frequency 
Intervention form and dose Control Key findings 
intervention 
versus control 
(Cormie et al. 
2013) 
Rating of Perceived Exertion 
Scale + unsupervised AET 
 
symptoms
(f) 
↔ BW 
↑ kg LBM
(l) 
↔ kg FM
 
or % 
FM
 (l)
 
↔ glucose, TC, 
TG, LDL or 
HDL 
Galvao, 2014 
(Galvao et al. 
2014) 
2-arm 100 Not reported 24 weeks; supervised 2 
days/week, unsupervised 2 
days/week 
Supervised, small group, 2-4 sets 
RET (12 to 16 RM) + 20-30 
minutes AET at 70-85% MHR 
and 11-13 Borg Rating of 
Perceived Exertion Scale + 
unsupervised AET. 
Usual care + 
pedometer and 
modified 
educational 
booklet 
↔ QoL
(d) 
↔ BW or WC 
↔ kg LBM, kg 
FM or  % FM
(l) 
↓ TC 
 
↑ HDL 
↔ glucose, TG 
or LDL 
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First Author, 
year 
Design Sample Duration of 
ADT 
Intervention duration and  
frequency 
Intervention form and dose Control Key findings 
intervention 
versus control 
↔ systolic or 
diastolic BP 
Segal, 2009 
(Segal et al. 
2009); 
Alberga, 
2012 
(Alberga et 
al. 2012) 
3-arm 121 102.9±166.3 
days 
24 weeks; 3 days/week 2 sets supervised RET, 8-12 
repetitions at 60-70% of 1 RM. 
 
15-45  minutes supervised AET 
at 50-60% to 70-75% MHR 
Usual care RET: 
↔ HRQoL
(a) 
↔ DQoL
(b) 
↓ fatigue
(c) 
↔ BW or BMI 
↓ % FM
(l) 
↑ kg LBM
(l) 
AET: 
↔ HRQoL
(a) 
↔ DQoL
(b) 
↔ fatigue
(c) 
↔ BW 
↓ BMI 
↔ kg LBM or 
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First Author, 
year 
Design Sample Duration of 
ADT 
Intervention duration and  
frequency 
Intervention form and dose Control Key findings 
intervention 
versus control 
% FM
(l)
 
Sharma, 
2009 
(Sharma et 
al. 2009); 
Napora, 2011 
(Napora et al. 
2011) 
2-arm 33 ≥3 months 12weeks; 1/day 20g powder soy protein 160 mg 
of total isoflavones (64 mg 
genistein, 63 mg daidzein, 34 mg 
glycitein) mixed in beverage. 
20 g powder 
whole milk 
↔ HRQoL
(d) 
↔ BW or BMI 
↔ libido or 
erectile 
function
(m)(n) 
↔ Sleep 
quality
(o) 
↑ Hot flashes
(p) 
↔ glucose, TC, 
TG, HDL or 
LDL 
Uth, 2014 
(Uth et al. 
2014) 
2-arm 57 ≥6 months 12weeks; 2 days/week 
(weeks 1-8), 3 days/week 
(weeks 9-12) 
15 minutes warm up + 2-3 15 
minutes football games 
Usual care ↑ kg LBM
(l) 
↔ kg FM
(
or % 
FM
(l) 
↔ WHR 
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First Author, 
year 
Design Sample Duration of 
ADT 
Intervention duration and  
frequency 
Intervention form and dose Control Key findings 
intervention 
versus control 
Vitolins, 2013 
(Vitolins et al. 
2013) 
4-arm 120  12 weeks; 1/day Placebo venflaxine + 20g powder 
soy protein (160mg isoflavones) 
Placebo 
venflaxine + 
20g milk 
powder 
↑ HRQoL
(a) 
↑ DQOL
(b)
 
↔ Hot flashes
(j) 
Abbreviations: ADT, androgen deprivation therapy; RET, resistance exercise training; AET aerobic exercise training; RM, repetition maximum; MHR, maximal 2 
heart rate; HRQoL, health-related quality of life; DQoL, disease-specific quality of life; BW, body weight; BMI, body mass index; WHR, waist-hip ratio; LBM, 3 
lean body mass; FM, fat mass; BP, blood pressure; WC, waist circumference; TC, total cholesterol; TG, triglycerides; LDL, low density lipoprotein cholesterol; 4 
HDL, high density lipoprotein cholesterol. 5 
(a) FACT-G, Functional Assessment of Cancer Therapy-general 6 
(b) FACT-P, FACT-prostate 7 
(c) FACT-F, FACT-fatigue 8 
(d) SF-36, 36-Item Short-Form Health Survey, general score.  9 
(e) EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer quality of life questionnaire 10 
(f) EORTC QLQ-PR25, EORTC prostate cancer-specific quality of life questionnaire 11 
(g) CES-D, Centers for Epidemiologic Studies-Depression 12 
(h) STAI, State Scale of the State/Trait Anxiety Inventory 13 
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(i) EPIC, Expanded prostate cancer index composite 14 
(j) HFSSS, Hot Flash Symptom Severity Score 15 
(k) FSS, fatigue 16 
(l) DXA, dual X-ray absorptiometry 17 
(m) Watts questionnaire 18 
(n) Index of Erectile Function 19 
(o) Epsworth Sleepiness Scale 20 
(p) Blatt-Kupperman 21 
 22 
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